Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma.

M. M. Walther, S. B. Jennings, P. L. Choyke, M. Andrich, K. Hurley, W. M. Linehan, S. A. Rosenberg, R. B. Alexander

Research output: Contribution to journalReview article

Abstract

Patients with localized renal-cell carcinoma who are candidates for renal parenchymal sparing surgery are being treated with isolated renal perfusion with recombinant human tumor necrosis factor (TNF). Isolated organ perfusion is a surgical technique that allows a cancer-bearing organ or region of the body to be treated with high doses of chemotherapy or biologic, agents that would not be tolerated systemically. In patients with in-transit melanoma or unresectable sarcoma, treatment with hyperthermic isolated limb perfusion using TNF, interferon-gamma, and melphalan has resulted in response rates exceeding 90%. Because preclinical studies suggest that TNF may induce regression of tumors by causing hemorrhagic necrosis mediated by effects on tumor-related vascular endothelium, a vascular tumor such as renal-cell carcinoma could potentially be very responsive. A phase I study of escalating TNF doses delivered via isolated renal perfusion is currently being conducted.

Original languageEnglish (US)
Pages (from-to)S2-7
JournalWorld journal of urology
Volume14 Suppl 1
DOIs
StatePublished - 1996

    Fingerprint

ASJC Scopus subject areas

  • Urology

Cite this

Walther, M. M., Jennings, S. B., Choyke, P. L., Andrich, M., Hurley, K., Linehan, W. M., Rosenberg, S. A., & Alexander, R. B. (1996). Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. World journal of urology, 14 Suppl 1, S2-7. https://doi.org/10.1007/bf00182056